CardioComm Solutions Responds to Cyber Security Incident
CardioComm Solutions Responds to Cyber Security Incident
Toronto, Ontario--(Newsfile Corp. - July 25, 2023) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces a cyber security incident on the Company's servers.
安大略省多伦多-(Newsfile Corp.-2023年7月25日)-美国心脏通讯解决方案公司(TSXV：EKG)(“心电联动“或”公司)，一家提供消费者心脏监测和医疗心电(“ECG”)软件解决方案的全球医疗供应商，宣布公司服务器上发生了一起网络安全事件。
The Company has launched a comprehensive investigation to fully ascertain the source and extent of any data breach and is working closely with KPMG-EGYDE, relevant authorities and third-party cybersecurity experts to support these efforts in accordance with industry best practices.
本公司已展开全面调查，以全面确定任何数据泄露的来源和程度，并正与毕马威-EGYDE、相关当局和第三方网络安全专家密切合作，根据行业最佳实践支持这些努力。
CardioComm's business operations will be impacted for several days and potentially longer depending how quickly the Company is able to restore its data and re-establishes its production server environments. There is no evidence that customers' health information was compromised as a result of this attack since CardioComm's software is designed to run on each client's own server environments. Further, CardioComm does not collect patient health information from its clients. The Company has initiated identity theft precautions should any employee personal information have been compromised to minimize the impact on its staff.
心脏通信公司的业务运营将受到数天甚至更长时间的影响，这取决于该公司恢复其数据和重建其生产服务器环境的速度。没有证据表明客户的健康信息因这次攻击而受到损害，因为心脏通信公司的软件被设计为在每个客户自己的服务器环境上运行。此外，心脏通讯公司不从其客户那里收集患者的健康信息。如果任何员工的个人信息被泄露，公司已启动身份盗窃预防措施，以将对员工的影响降至最低。
The Company also provides an update respecting the Cease Trade Order (the "CTO") issued by the Ontario Securities Commission and the suspension of trading imposed by the TSX Venture Exchange due to the late filing of the Company's annual financial statements for the financial year ended December 31, 2022 (the "Financial Statements") and its management's discussion and analysis relating to the Financial Statements (collectively, the "Required Filings") before the prescribed deadline of May 1, 2023 (see the Company's press releases dated May 1, 2023 and May 10, 2023 for further details). Although unexpectedly delayed by the security incident, the Company continues to work with its auditor to finalize the Required Filings, which are anticipated to be filed prior to the end of the 90 day CTO term, following which the Company will apply for reinstatement for trading on the TSX Venture Exchange. The Company will provide updates as warranted.
公司还提供了关于安大略省证券委员会发布的停止交易令(“CTO”)和多伦多证券交易所因延迟提交公司截至2022年12月31日的财政年度财务报表(“财务报表”)而被多伦多证券交易所暂停交易的最新情况，以及管理层在规定的截止日期2023年5月1日之前与财务报表相关的讨论和分析(统称为“要求提交的财务报表”)的最新情况(详情请参阅公司日期为2023年5月1日和2023年5月10日的新闻稿)。尽管安全事件意外推迟，但公司仍在继续与其审计师合作，以最终确定所需的申报文件，这些申报文件预计将在90天的CTO期限结束前提交，之后公司将申请恢复在多伦多证券交易所创业板交易。公司将在保证的情况下提供更新。
To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at and .
欲了解更多有关HearoComm公司产品的信息，以及有关HeartCheck心电设备集成的进一步更新，请访问该公司的网站和。
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
关于心通解决方案
心脏通讯解决方案公司的专利和专有技术用于记录、观看、分析和存储心电，用于心脏病患者的诊断和管理。产品通过外部分销网络和北美销售团队销往世界各地。心脏通信解决方案公司已获得国际标准化组织13485和国际标准化组织27001认证，符合美国国际药品监督管理局的要求，并持有美国食品和药物管理局和加拿大卫生部颁发的医疗器械许可和销售许可证。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
欲了解更多信息，请联系：
首席执行官艾蒂安·格里马
1-877-977-9425转227
邮箱：Investor.Relationship@Hearocomsoltions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
前瞻性陈述
本新闻稿可能包含有关心脏通信解决方案公司的财务状况、经营和业务结果以及心脏通信解决方案公司与这些项目有关的某些计划和目标的前瞻性陈述和前瞻性信息。这些陈述和信息反映了管理层目前的信念，并以管理层目前掌握的信息为基础。就其性质而言，前瞻性陈述和前瞻性信息涉及风险和不确定性，因为它们与事件有关，并取决于未来发生的情况，而且有许多因素可能导致实际结果和事态发展与这些前瞻性陈述和前瞻性信息明示或暗示的情况大不相同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在评估这些陈述时，读者不应过分依赖前瞻性陈述和前瞻性信息。除适用法律要求外，公司不承担更新本新闻稿中包含的前瞻性陈述和前瞻性信息的任何义务，包括但不限于国家文书51-102(持续披露义务)。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问
译文内容由第三方软件翻译。